替奈普酶与阿替普酶静脉溶栓联合强化阿托伐他汀治疗急性缺血性脑卒中的临床疗效对比研究

Comparative Study of the Clinical Efficacy of Teneplase versus Alteplase Intravenous Thrombolysis Combined with Intensive Atorvastatin in the Treatment of Acute Ischemic Stroke

摘要: 目的：比较替奈普酶与阿替普酶静脉溶栓后分别联用强化阿托伐他汀方案治疗急性缺血性脑卒中的临床疗效及安全性差异。方法：采用平行对照设计，以本院急诊内科99例AIS患者为研究对象，替奈普酶组49例，阿替普酶组50例，分别予以替奈普酶、阿替普酶联合强化阿托伐他汀钙治疗。比较两组一般临床资料、美国国立卫生研究院卒中量表评分、改良Rankin量表评分、溶栓后出血不良事件、血脂指标。结果：与阿替普酶组相比，替奈普酶组治疗后NIHSS评分和90 d mRS评分降低更多，口腔粘膜出血发生率更低。结论：与阿替普酶相比，替奈普酶联合阿托伐他汀钙治疗急性缺血性脑卒中患者临床疗效更好，且安全性更高。

Abstract: Objective: To compare the clinical efficacy and safety differences between teneplase and alteplase intravenous thrombolysis followed by an intensive atorvastatin regimen in combination with teneplase and alteplase, respectively, for the treatment of acute ischemic stroke. Methods: Using a parallel control design, 99 patients with AIS in the Department of Emergency Medicine of our hospital, 49 in the teneplase group and 50 in the alteplase group, were treated with teneplase and alteplase combined with intensive atorvastatin calcium, respectively. General clinical data, National Institutes of Health Stroke Scale score, modified Rankin Scale score, post-thrombolytic bleeding events, and blood lipids were compared between the two groups. Results: The teneplase group had a greater reduction in post-treatment NIHSS score, 90 d mRS score, and a lower incidence of oral mucosal bleeding compared with the alteplase group. Conclusion: Teneplase combined with atorvastatin calcium is clinically more effective and safe compared with alteplase in the treatment of patients with acute ischemic stroke.